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Abstract 37 
Cancer-associated systemic inflammation is strongly linked with poor disease outcome in 38 
cancer patients1,2. For most human epithelial tumour types, high systemic neutrophil-to-39 
lymphocyte ratios are associated with poor overall survival3, and experimental studies have 40 
demonstrated a causal relationship between neutrophils and metastasis4,5. However, the 41 
cancer cell-intrinsic mechanisms dictating the substantial heterogeneity in systemic 42 
neutrophilic inflammation between tumour-bearing hosts are largely unresolved. Using a panel 43 
of 16 distinct genetically engineered mouse models (GEMMs) for breast cancer, we have 44 
uncovered a novel role for cancer cell-intrinsic p53 as a key regulator of pro-metastatic 45 
neutrophils. Mechanistically, p53 loss in cancer cells induced secretion of Wnt ligands that 46 
stimulate IL-1β production by tumour-associated macrophages, which drives systemic 47 
inflammation. Pharmacological and genetic blockade of Wnt secretion in p53-null cancer cells 48 
reverses IL-1β expression by macrophages and subsequent neutrophilic inflammation, 49 
resulting in reduced metastasis formation. Collectively, we demonstrate a novel mechanistic 50 
link between loss of p53 in cancer cells, Wnt ligand secretion and systemic neutrophilia that 51 
potentiates metastatic progression. These insights illustrate the importance of the genetic 52 
makeup of breast tumours in dictating pro-metastatic systemic inflammation, and set the stage 53 
for personalized immune intervention strategies for cancer patients. 54 
55 
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Main text 56 
To determine how pro-metastatic systemic inflammation is influenced by genetic aberrations 57 
in tumours, we studied 16 GEMMs for breast cancer carrying different tissue-specific 58 
mutations. These GEMMs represent most subtypes of human breast cancer, including ductal 59 
and lobular carcinoma, oestrogen receptor-positive (luminal A), HER2+, triple-negative and 60 
basal-like breast cancer. Because we and others have demonstrated that neutrophils expand 61 
systemically and promote metastasis5-10, we evaluated circulating neutrophil levels as a marker 62 
for systemic inflammation in mammary tumour-bearing mice with end-stage disease. As 63 
expected, most tumour-bearing mice displayed an increase in circulating neutrophils as 64 
compared to non-tumour-bearing animals (wild-type [WT]) (Fig. 1a). Like the inter-patient 65 
heterogeneity in systemic inflammation in human breast cancer11, we observed a striking 66 
variability in the extent of neutrophilia between the different tumour-bearing GEMMs (Fig. 1a, 67 
Extended Data Fig. 1a). We found that the models exhibiting high neutrophil expansion 68 
displayed a subset of neutrophils expressing the stem cell marker cKIT (Fig. 1b), indicative of 69 
an immature neutrophil phenotype5. We subsequently searched for commonalities and 70 
differences among the 16 GEMMs with regards to high versus low systemic neutrophil levels. 71 
Strikingly, mice bearing tumours with a p53 deletion exhibited the most pronounced circulating 72 
neutrophil levels (Fig. 1a). The difference in magnitude of systemic inflammation between p53-73 
proficient and p53-null tumours was even more apparent when focusing on cKIT+ neutrophils 74 
(Fig. 1b).  75 
In mouse models for colorectal, pancreatic, prostate and endometrial cancer, p53 76 
mutation or loss leads to recruitment and activation of immune cells in the primary tumour 77 
microenvironment12-16. To study the association between p53 status of the tumour and 78 
systemic inflammation, we separated the 16 GEMMs based on the presence or absence of 79 
homozygously floxed Trp53 alleles and compared the levels of circulating neutrophils and the 80 
proportion of cKIT-expressing neutrophils. This analysis confirmed a statistically significant 81 
difference between mice bearing p53-proficient and p53-null tumours (Fig. 1c, d).  82 
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We previously demonstrated that expansion of neutrophils in mammary tumour-bearing 83 
K14-cre;Cdh1F/F;Trp53F/F (KEP) mice is driven by an inflammatory pathway involving CCL2, 84 
IL-1β, IL-17A and G-CSF5,17. We found that serum levels of CCL2, IL-1 and G-CSF correlated 85 
with p53 loss in primary tumours in the 16 GEMMs (Fig. 1e–h). Principal component analysis 86 
of these systemic immune parameters further demonstrated that systemic inflammation 87 
correlated with p53 status of the tumour (Fig. 1i).  88 
To provide evidence for a causal relationship between p53-loss in mammary tumours 89 
and neutrophilia, we derived cancer cell lines from two independent p53-proficient tumour 90 
models, Wap-cre;Cdh1F/F;AktE17K (WEA)18 and Wap-cre;Cdh1F/F;Pik3caE545K (WEP). Using 91 
CRISPR/Cas9-mediated gene disruption, we targeted Trp53, which resulted in an inability to 92 
increase p21 levels after irradiation (Extended Data Fig. 2a, b, e). We orthotopically 93 
transplanted WEA;Trp53+/+ and WEP;Trp53+/+ cells, and matched WEA;Trp53–/– and 94 
WEP;Trp53–/– cells into syngeneic WT mice (Fig. 2a). While p53-loss conferred a proliferation 95 
advantage in vitro, in vivo growth kinetics were similar between p53-proficient and -deficient 96 
tumours for both cell lines (Extended Data Fig. 2c–g). Consistent with our findings in the GEMM 97 
panel, we observed increased expansion of neutrophils, including cKIT+ neutrophils, in the 98 
circulation and lungs of mice bearing WEA;Trp53–/– and WEP;Trp53–/– tumours, when 99 
compared to mice bearing size-matched p53-proficient tumours (Fig. 2b–d, Extended Data 100 
Fig. 2h, i). In addition, mice with WEA;Trp53–/–, but not WEP;Trp53–/– tumours, presented with 101 
splenomegaly when compared to Trp53+/+ controls (Extended Data Fig. 2j), a phenomenon 102 
often observed in inflammation and cancer19. These data reveal that loss of p53 in breast 103 
cancer cells is a central driving event of cancer-induced systemic neutrophilic inflammation. 104 
Since we observed cKIT+ immature neutrophils in p53-null tumour-bearing mice (Fig. 105 
1d, 2d), we next investigated whether haematopoiesis was altered. In mice bearing 106 
WEA;Trp53–/– tumours, frequencies of Lin—Sca1+cKIT+ cells (LSKs), common myeloid 107 
progenitors (CMPs), CD11b+Ly6Glow pro-myelocytes and mature neutrophils were increased 108 
in the bone marrow at the expense of megakaryocyte and erythrocyte progenitors (MEPs), 109 
when compared to WEA;Trp53+/+ tumour-bearing mice (Extended Data Fig. 3a–c). This effect 110 
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on cell proportions was not reflected in the total cell counts, possibly due to a slight depletion 111 
of total bone marrow cell numbers in WEA;Trp53–/– tumour-bearing mice (Extended Data Fig. 112 
3d).  113 
Previously, we reported that macrophage-derived IL-1 in the tumour 114 
microenvironment triggers systemic neutrophil expansion in KEP mice5. Since IL-1 serum 115 
levels correlated with p53 status (Fig. 1f) we hypothesized that loss of p53 changes the 116 
secretome of cancer cells, stimulating IL-1 production from tumour-associated macrophages 117 
(TAMs) and setting off a systemic inflammatory cascade. Indeed, in vitro exposure of bone 118 
marrow-derived macrophages (BMDMs) to conditioned medium (CM) from WEA;Trp53–/– or 119 
WEA;Trp53+/+ cancer cells differentially affected their phenotype (Extended Data Fig. 4a). 120 
Notably, CM from WEA;Trp53–/– and WEP;Trp53–/– cells strongly induced Il1b mRNA 121 
expression in cultured BMDMs as compared to CM from matched Trp53+/+ controls (Fig. 2e). 122 
In agreement with our mouse data, human monocyte-derived macrophages (hMDMs) cultured 123 
with tumour CM of TP53–/– MCF-7 human breast cancer cells displayed increased CD206 and 124 
CD163 expression compared to hMDMs cultured with CM of p53-proficient MCF-7 cells 125 
(Extended Data Fig. 4c). We also observed increased IL1B expression in hMDMs upon 126 
exposure to TP53–/– MCF-7 cells compared to TP53+/+ controls (Extended Data Fig. 4d). These 127 
data indicate that cancer cell-intrinsic p53 status dictates the crosstalk between cancer cells 128 
and macrophages in a paracrine fashion, resulting in an altered macrophage phenotype and 129 
IL-1 production. We also observed elevated levels of IL1B mRNA expression in breast 130 
tumours of The Cancer Genome Atlas (TCGA) with mutations in TP53 (TP53MUT) compared to 131 
TP53WT tumours (Fig. 2f), suggesting similar p53-dependent activation of IL-1 signalling in 132 
human breast cancer. 133 
To identify which factor(s) in p53-null tumours mediate TAM activation and subsequent 134 
systemic inflammation, we performed RNA sequencing on mammary tumours of 12 different 135 
GEMMs (7 p53-null models, 5 p53-proficient models; 145 tumours in total). The p53-deficient 136 
tumours differed substantially from p53-proficient tumours in terms of gene expression, 137 
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regardless of any additional genetic aberrations, demonstrating a dominant effect of p53-loss 138 
on the global transcriptome (Extended Data Fig. 5a). Interestingly, the most significantly 139 
changed pathways in p53-deficient tumours pertained to adaptive immune phenotypes (Fig. 140 
3a). While neutrophil and TAM numbers were altered intratumourally, the composition of CD8+, 141 
CD4+ or FOXP3+ T cells did not correlate with p53-status (Extended Data Fig. 5b–g), 142 
suggesting that the distinct transcriptome profiles are not due to a p53-dependent effect on the 143 
composition of the adaptive immune landscape. 144 
From the gene ontology analysis, we selected genes encoding secreted factors that 145 
could potentially influence TAMs. One of the up-regulated pathways in p53-null tumours 146 
included WNT/-catenin signalling (Fig. 3a). WNT signalling is linked to IL-1 production in 147 
acute arthritis, as well as immune and stromal signalling in cancer20-23. Using a WNT/-catenin 148 
signalling gene signature, we found that p53-null GEMM tumours clustered separately from 149 
p53-proficient tumours, indicating an association between p53-loss and WNT-related gene 150 
expression (Extended Data Fig. 6a, b). Many WNT-related genes were up-regulated in p53-151 
deficient tumours, including three WNT ligands, Wnt1, Wnt6 and Wnt7a, while expression of 152 
negative regulators of WNT signalling was decreased (Fig. 3b, Extended Data Fig. 6c). 153 
Elevated protein levels of WNT1 and WNT7A were confirmed in a set of independent p53-154 
deficient tumours (Fig. 3c, d). We also found increased expression of non-phosphorylated -155 
catenin, indicative of activated WNT signalling (Fig. 3c, d). In human breast tumours, 156 
expression of WNT1, WNT6 and WNT7A was increased upon aberrant expression of TP53, 157 
compared to TP53WT tumours (Fig. 3e). We then broadened our analysis of TCGA data to 158 
other WNT-related genes and discovered a trend towards enrichment of these genes in TP53-159 
mutated tumours (Extended Data Fig. 6d). Additionally, individual WNT-stimulating genes 160 
were upregulated, while WNT-inhibiting genes were downregulated in TP53MUT versus TP53WT 161 
human tumours (Extended Data Fig. 6e), indicating that WNT signalling is activated upon 162 
aberrant expression of TP53. Using WEA cell lines, we confirmed that WNT1, WNT6 and 163 
WNT7A proteins are increased intracellularly in WEA;Trp53–/– cells and secreted, when 164 
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compared to WEA;Trp53+/+ cells (Fig. 3f). Collectively, these data indicate cancer cell-165 
autonomous WNT ligand secretion upon loss of p53.  166 
Since deletion of p53 increases WNT ligand expression, we hypothesized that wild-167 
type p53 negatively regulates these genes, either directly or indirectly. To determine whether 168 
p53 binds the regulatory regions of Wnt1, Wnt6 and/or Wnt7a, we performed chromatin 169 
immunoprecipitation-sequencing (ChIP-seq) in 3 independent WEA and WEP cell lines. p53 170 
binding was observed at the Cdkn1a (p21) locus (Extended Data Fig. 7a), whereas we did not 171 
find p53 binding at the Wnt1, Wnt6 or Wnt7a loci (Extended Data Fig. 7b), suggesting that p53 172 
regulates their expression indirectly. Since p53 has been described to control Wnt1 expression 173 
by activating microRNA-34a (miR-34a)24, we wondered whether this microRNA may be 174 
involved in the regulation of Wnt1, Wnt6 and Wnt7a. Indeed, we observed p53 chromatin 175 
binding at the miR-34a locus in all cell lines (Extended Data Fig. 7c). Overexpression of miR-176 
34a in WEA;Trp53–/– cells resulted in a significant reduction of WNT ligand expression 177 
(Extended Data Fig. 7d). These data suggest that wild-type p53 negatively regulates the 178 
expression of Wnt1, Wnt6 and Wnt7a via miR-34a.   179 
We then assessed the role of cancer cell-derived WNT ligands on IL-1 production by 180 
macrophages. We treated WEA cells with LGK974 – which inhibits Porcupine (Porcn), a Wnt-181 
specific acyltransferase that regulates WNT ligand secretion25 – and added CM to 182 
macrophages. LGK974 reduced the WEA;Trp53–/– cell-induced Il1b expression by 183 
macrophages (Fig. 4a). We also depleted Porcn in WEA;Trp53–/– cells using short hairpin 184 
RNAs (shRNA) and knockdown reduced Il1b expression by macrophages, consistent with 185 
pharmacological Porcupine inhibition (Fig. 4a). These data confirm a causal relationship 186 
between WNT ligand secretion by p53-deficient cancer cells and IL-1 expression in 187 
macrophages.  188 
To identify the receptors involved in the crosstalk between p53-null cancer cells and 189 
macrophages, we looked for genes encoding WNT receptors in the GEMM gene expression 190 
data. We found that Frizzled receptors, Fzd7 and Fzd9, were up-regulated in the p53-null 191 
tumours compared to p53-proficient tumours (Extended Data Fig. 8a). Similarly, FZD7 and 192 
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FZD9 were increased in expression in TP53MUT human breast tumours compared to TP53WT 193 
tumours (Extended Data Fig. 8b). We then used small interfering RNAs (siRNA) to knockdown 194 
both Fzd7 and Fzd9 in BMDMs (Extended Data Fig. 8c), which prevented Il1b induction by 195 
WEA;Trp53–/– cells (Extended Data Fig. 8d), demonstrating that that FZD7 and FZD9 are 196 
involved in WNT-induced activation of macrophages in vitro.  197 
We next assessed whether WNT ligand production by p53-deficient cancer cells drives 198 
systemic inflammation. We treated tumour-bearing KEP mice with LGK974 for five consecutive 199 
days and this led to a reduction in total neutrophils and cKIT+ neutrophils in blood and lungs 200 
when compared to vehicle-treated KEP mice (Fig. 4b, Extended Data Fig. 9a). Additionally, IL-201 
17A-producing  T cells – the key cell type responding to IL-1 that drive neutrophil 202 
accumulation and consequently metastasis5 – were reduced in the lungs of LGK974-treated 203 
KEP mice (Extended Data Fig. 9b), indicating that  T cell activation upstream of pro-204 
metastatic neutrophil accumulation depends on WNT signalling. Similarly, long-term treatment 205 
of KEP mice with LGK974 blocked neutrophil expansion over time (Extended data Fig. 9c). To 206 
exclude that the observed reduction in inflammation is a result of targeting non-tumour cells 207 
by LGK974, we orthotopically transplanted WEA;Trp53–/–;shPorcn cell lines and matched 208 
WEA;Trp53–/–;shControl cells into WT mice. Analysis of size-matched end-stage tumours 209 
revealed an incomplete reduction of Porcn expression (Extended Data Fig. 9d). Although we 210 
cannot formally exclude the possibility that non-cancer cells contribute to the residual Porcn 211 
expression, expression levels of Porcn in the tumours correlated with circulating neutrophils, 212 
cKIT+ neutrophils and Il1b expression (Extended Data Fig. 9e–g). Moreover, knockdown of 213 
Porcn prevented splenomegaly (Extended Data Fig. 9h). Collectively, these data confirm the 214 
causal link between WNT secretion triggered by p53-deficient mammary tumours and systemic 215 
inflammation. 216 
Since the  T cell–neutrophil axis promotes metastasis4,5 and these cells are regulated 217 
by WNT ligands, we hypothesized that LGK974 treatment may present a viable therapeutic 218 
strategy to inhibit metastasis of p53-null mammary tumours. To test this, we treated KEP 219 
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tumour-bearing mice with LGK974 or vehicle, after which we surgically removed the primary 220 
tumour and assessed metastatic progression. Strikingly, while Porcupine blockade did not 221 
affect primary tumour growth (Extended Data Fig. 9i), pulmonary metastases were reduced 222 
(Fig. 4c, d). In an independent metastasis model in which we orthotopically transplanted 223 
matched Trp53+/+ and Trp53–/– WEP cell lines, we observed that the absence of p53 increases 224 
lung metastasis formation (Fig. 4e, left and right graphs; P=0.0153). We then treated both 225 
WEP;Trp53+/+ and WEP;Trp53–/– tumour-bearing mice with LGK974, which failed to influence 226 
primary tumour growth (Extended Data Fig. 9j). However, LGK974 treatment reduced 227 
metastasis of WEP;Trp53–/– tumours, without affecting metastasis of WEP;Trp53+/+ tumours 228 
(Fig. 4e, f). These data show that blocking WNT-induced systemic inflammation impedes 229 
metastasis formation of p53-null mammary tumours.  230 
In summary, we show that p53 status is an important driver of systemic pro-metastatic 231 
inflammation in breast cancer (Extended Data Fig. 9k) and that targeting WNT signalling may 232 
represent a promising therapeutic modality for patients with p53-deficient breast tumours. 233 
Together with recent literature on the importance of canonical driver mutations in shaping the 234 
local immune composition of primary tumours26, our findings shed light on the poorly 235 
understood inter-patient heterogeneity in the systemic composition and function of immune 236 
cells. Mechanistic understanding of the intricate interactions between cancer cell-intrinsic 237 
genetic events and the immune landscape provides a basis for the design of personalized 238 
immune intervention strategies for cancer patients. 239 
240 
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Figure legends 242 
 243 
Figure 1: Loss of p53 in mammary cancer cells correlates with systemic neutrophilic 244 
inflammation. a. Flow cytometry analysis of frequency of CD11b+Ly6G+Ly6C+ neutrophils and 245 
b. proportion of cKIT+ neutrophils as determined by flow cytometry analysis on blood of breast 246 
cancer GEMMs at end-stage (cumulative tumour volume 1500 mm3) and non-tumour-bearing 247 
(WT) controls (n=4, 3, 4, 7, 3, 4, 4, 3, 6, 7, 6, 9, 3, 5, 4, 7 and 7 mice, top to bottom). Asterisks 248 
indicate statistically significant differences compared to WT. * P < 0.05, ** P < 0.01, *** P < 249 
0.001, **** P < 0.0001. c. Total neutrophil frequencies and d. cKIT+ neutrophil frequencies in 250 
circulation of all Trp53+/+ (n=28) and Trp53–/– (n=46) tumour-bearing mice, combined from a. 251 
and b. e. CCL2 levels (n=17 Trp53+/+, n=22 Trp53–/–), f. IL-1 levels (n=18 Trp53+/+, n=21 252 
Trp53–/–), g. IL-17A levels (n=24 Trp53+/+, n=30 Trp53–/–) and h. G-CSF levels (n=22 Trp53+/+, 253 
n=33 Trp53–/–) in serum of GEMMs at end-stage based on p53 status. i. Principal component 254 
analysis of data depicted in a – h (13 out of 16 GEMMs). Each symbol represents one mouse. 255 
Circles contour 40% of group-specific Gaussian probability distributions of sample scores. All 256 
data are means ± s.e.m., P-values are indicated as determined by two-tailed one-way ANOVA, 257 
Tukey’s multiple-testing correction (a, b) or two-tailed Mann-Whitney U-test (c – h).      258 
 259 
Figure 2. p53 status in mammary tumours dictates immune activation. a. Experimental 260 
setup: cell lines are derived from Trp53+/+ tumours (Wap-cre;Cdh1F/F;AktE17K (WEA) and Wap-261 
cre;Cdh1F/F;Pik3caE545K (WEP)) and p53 is knocked out (KO) using CRISPR/Cas9. KO and 262 
control cell lines are orthotopically transplanted into syngeneic mice. b. Frequency of total 263 
CD11b+Ly6G+Ly6C+ neutrophils in circulation and c. in lungs, and d. frequency of cKIT+ 264 
neutrophils (% of total neutrophils) in circulation at end-stage (tumour volume 1500 mm3) of 265 
mice with Trp53+/+ and Trp53–/– WEA and WEP tumours, as determined by flow cytometry (n=4 266 
WEA;Trp53+/+, n=6 WEA;Trp53–/–, n=5 WEP;Trp53+/+, n=5 WEP;Trp53–/–). e. RT-qPCR 267 
analysis of the expression of Il1b in bone marrow-derived macrophages (BMDM) after 268 
exposure to conditioned medium of Trp53+/+ and Trp53–/– WEA (n=4 biological 269 
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replicates/group) or WEP cell lines (n=3 biological replicates/group). Plots show representative 270 
of 3 independent experiments with 2 technical replicates per biological replicate. f. IL1B 271 
expression in TP53 wild-type (WT, n=643) or TP53 mutant (MUT, n=351) human breast 272 
tumours of The Cancer Genome Atlas (TCGA) database. Data in b – e are means ± s.e.m., f. 273 
shows 5 – 95 percentile boxplot with median and quartiles indicated. P-values are indicated 274 
as determined by two-tailed Mann-Whitney U-test (b, c, d, f) or two-tailed one-way ANOVA, 275 
Tukey’s multiple-testing correction (e). 276 
 277 
Figure 3. p53-null tumours display activated Wnt signalling. a. Top 10 most significantly 278 
differentially activated pathways determined by Ingenuity Pathway Analysis, comparing Trp53–279 
/– (n=77) with Trp53+/+ (n=68) GEMM tumours of 12 different models. Also indicated is the Wnt 280 
signalling pathway. b. Log2 fold change expression of Wnt1, Wnt6 and Wnt7a in Trp53–/– (n=77) 281 
GEMM tumours compared to Trp53+/+ (n=68) tumours. c. Western blot analysis of bulk tumours 282 
showing non-phospho(active)--catenin, Porcupine, Wnt1, Wnt6 and Wnt7a (blue indicates 283 
Trp53–/– tumours and red indicates Trp53+/+ tumours). Representative of two independent 284 
experiments. For uncropped images, see Supplemental Fig. 1. d. Quantification of c 285 
(n=3/group). e. Expression of WNT1, WNT6 and WNT7A in TP53 wild-type (WT, n=643) and 286 
TP53 mutant (MUT, n=351) human breast tumours of TCGA breast cancer database. f. 287 
Western blot analysis on cell lysate and conditioned medium of Wap-288 
cre;Cdh1F/F;AktE17K;Trp53+/+ (WT) and Wap-cre;Cdh1F/F;AktE17K;Trp53–/– (KO) cell lines for Wnt 289 
ligands. Representative of two independent experiments. d. shows mean ± s.e.m., e shows 5 290 
– 95 percentile boxplot with median and quartiles indicated. P-values are indicated as 291 
determined by two-tailed one-way ANOVA, FDR multiple-testing correction (b) or two-tailed 292 
Mann-Whitney U-test (d, e). 293 
 294 
Figure 4. Wnt-induced systemic inflammation promotes metastasis. a. RT-qPCR analysis 295 
of bone marrow-derived macrophages (BMDM) after exposure to control medium or 296 
conditioned medium from Wap-cre;Cdh1F/F;AktE17K;Trp53+/+ (WT), Wap-297 
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cre;Cdh1F/F;AktE17K;Trp53–/– (KO) or Wap-cre;Cdh1F/F;AktE17K;Trp53–/– cells transduced with 2 298 
independent shRNAs against Porcn (KO shPorcn-1 and KO shPorcn-4). Where indicated, cell 299 
lines were pre-treated with 1 µM LGK974 (KO + LGK974) (n=5 biological replicates/group for 300 
WT, WT + LGK974, KO and KO + LGK974, n=3 biological replicates for KO shPorcn-1 and 301 
KO shPorcn-4). Plots show representative data of 3 separate experiments with 2 technical 302 
replicates per biological replicate. b. Frequency of total CD11b+Ly6G+Ly6C+ neutrophils and 303 
cKIT+ neutrophils in circulation of K14cre;Cdh1F/F;Trp53F/F (KEP) mice after 5 day LGK974 304 
(n=4) or vehicle (n=7) treatment starting at tumour volume 500 mm3. c. Number of pulmonary 305 
metastases after KEP tumour-bearing mice were treated with LGK974 (n=15) or vehicle 306 
(n=12). KEP tumour fragments were orthotopically transplanted in FVB/N mice and treatment 307 
was initiated when tumours were 30 – 40 mm3 and continued until mastectomy. d. 308 
Representative images of cytokeratin-8 staining of lungs of KEP tumour-bearing mice. Scale 309 
bars, 1.9 mm. e. Number of pulmonary metastases after orthotopic injection of Trp53+/+ and 310 
Trp53–/– Wap-cre;Cdh1F/F;Pik3caE545K (WEP) cells and treatment with LGK974 or vehicle 311 
(n=9/group). Treatment was initiated when tumours were 30 – 40 mm3 and continued until 312 
1500 mm3. f. Representative images of cytokeratin-8 staining of lungs of WEP tumour-bearing 313 
mice, arrows indicate examples of metastatic nodules. Scale bars, 1.4 mm. All data are means 314 
± s.e.m. P-values are indicated as determined by two-tailed one-way ANOVA, Tukey’s 315 
multiple-testing correction (a) or two-tailed Mann-Whitney U-test (b, c, e), ns: non-significant. 316 
317 
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Methods 318 
 319 
Mice  320 
All animal experiments were approved by the Animal Ethics Committee of the Netherlands 321 
Cancer Institute and performed in accordance with institutional, national and European 322 
guidelines for Animal Care and Use. The generation and characterization of the mouse models 323 
has been described27-34 (and unpublished). The following mouse models were used in this 324 
study: Keratin14 (K14)-cre;Cdh1F/F;Trp53F/F, K14cre;Trp53F/F, K14cre;Brca1F/F;Trp53F/F, Whey 325 
Acidic Protein (Wap)-cre;Trp53F/F, Wap-cre;Brca1F/F;Trp53F/F, Wap-326 
cre;Brca1F/F;Trp53F/F;Col1a1invCAG-Met-IRES-Luc/+ (Wap-cre;Brca1F/F;Trp53F/F;Met), Wap-327 
cre;Brca1F/F;Trp53F/F;Col1a1invCAG-Myc-IRES-Luc/+ (Wap-cre;Brca1F/+;Trp53F/F;Myc), Wap-328 
cre;Brca1F/F;Trp53F/F;Col1a1invCAG-Myb2-IRES-Luc/+ (Wap-cre;Brca1F/F;Trp53F/F;Myb2), Wap-329 
cre;Trp53F/F;Col1a1invCAG-ESR1-IRES-Luc/+ (Wap-cre;Trp53F/F;HA-ESR1), Wap-330 
cre;Cdh1F/F;Col1a1invCAG-AktE17K-IRES-Luc/+ (Wap-cre;Cdh1F/F;AktE17K), Wap-331 
cre;Cdh1F/F;Col1a1invCAG-Pik3caE545K-IRES-Luc/+ (Wap-cre;Cdh1F/F;Pik3caE545K), Wap-332 
cre;Cdh1F/+;Col1a1invCAG-Fgfr2ex1-15-IRES-Luc/+ (Wap-cre;Cdh1F/+;Fgfr2ex1-15), Wap-333 
cre;Cdh1F/F;Col1a1invCAG-Fgfr2ex1-15-IRES-Luc/+ (Wap-cre;Cdh1F/F;Fgfr2ex1-15), Wap-334 
cre;Cdh1F/F;T2/Onc;Rosa26Lox66SBLox71/+ (Wap-cre;Cdh1F/F;SB), Wap-cre;Map3k1F/F;PtenF/F, 335 
Mouse mammary tumour virus LTR (MMTV)-NeuT. All mouse models were on FVB/N 336 
background, except MMTV-NeuT and Wap-cre;Cdh1F/F;SB, which were on Balb/c and a mixed 337 
genetic (C57BL/6J and FVB/N) background, respectively. Female mice were monitored twice 338 
weekly for the onset of spontaneous mammary tumour formation by palpation starting at 6-7 339 
weeks of age. The perpendicular tumour diameters of mammary tumours were measured twice 340 
per week using a calliper, and tumour volume was calculated using vol(mm3) = 0.5(length x 341 
width2). Maximum permitted tumour volumes were 1500 mm3. Age-matched WT littermates 342 
were used as controls. Average systemic total and cKIT+ neutrophil levels in non-tumour-343 
bearing FVB/N and Balb/c mice were similar (data not shown). For orthotopic transplantation 344 
experiments, 1x106 cells were injected into the right 4th mammary fat pad of WT FVB/N mice 345 
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(Janvier Labs). For intervention studies targeting Porcupine, K14cre;Cdh1F/F;Trp53F/F mice 346 
were treated daily with LGK97435 (10 mg/kg, in 10% DMSO/10% Cremophor in PBS) or vehicle 347 
(10% DMSO/10% Cremophor in PBS) via oral gavage, starting at matched tumour sizes 348 
indicated in the figures. For metastasis experiments, the KEP-based model for spontaneous 349 
breast cancer metastasis was used as previously described36. Briefly, tumour fragments of 350 
K14cre;Cdh1F/F;Trp53F/F mice were orthotopically transplanted into FVB/N mice and surgically 351 
removed when tumours reached 500 mm3 in size.  In this model, LGK974 treatment was 352 
initiated when tumours were 30 – 40 mm3 in size and continued until mastectomy, after which 353 
mice were monitored for signs of metastatic disease. Disease endpoint was defined as mice 354 
showing signs of respiratory distress or palpable metastatic nodules in lymph nodes or other 355 
organs reaching 1500 mm3 in size. For metastasis experiments using the Wap-356 
cre;Cdh1F/F;Pik3caE545K model, matched Trp53+/+ and Trp53–/– tumour-derived cell lines were 357 
orthotopically injected in the mammary fat pad of FVB/N mice (1x106 cells) and tumours were 358 
allowed to grow out until end stage (1500 mm3). During this time, tumours spontaneously 359 
metastasize to the lungs. LGK974 or vehicle treatment was initiated when tumours were 30 – 360 
40 mm3 and continued until end stage. Orthotopically transplanted WEA tumours did not 361 
spontaneously metastasize before the primary tumours reached 1500 mm3. For intervention 362 
studies, mice were randomly distributed over the two treatment arms when tumours reached 363 
the indicated size. Tumour measurements and post mortem analyses were performed in a 364 
blinded fashion. Mice were kept in individually ventilated cages, and food and water were 365 
provided ad libitum. The maximal tolerated disease endpoints were not exceeded in any of the 366 
experiments. 367 
 368 
Flow cytometry  369 
Flow cytometry analysis was performed as previously described5. Briefly, tissues were 370 
collected in ice-cold PBS and blood was collected in tubes containing heparin. Tumours and 371 
lungs were mechanically chopped using a McIlwain tissue chopper (Mickle Laboratory 372 
Engineering). Tumours were digested for 1 hour (h) at 37°C in 3 mg/mL collagenase type A 373 
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(Roche) and 25 µg/mL DNase (Sigma) in serum-free DMEM medium. Lungs were digested for 374 
30 minutes (min) at 37°C in 100 µg/mL Liberase TM (Roche). Enzyme reactions were stopped 375 
by addition of cold DMEM/8% Fetal Calf Serum (FCS) and suspensions were dispersed 376 
through a 70 µm cell strainer. Bone marrow was collected from the tibia and femurs of both 377 
hind legs and flushed using RPMI/8% FCS through a 70 µm cell strainer. Single-cell 378 
suspensions were treated with NH4Cl erythrocyte lysis buffer. Before staining, cell suspensions 379 
were subjected to Fc receptor blocking (rat anti-mouse CD16/32, BD Biosciences) for 15 min 380 
at 4°C, except for bone marrow (to allow assessment of CD16/32 expression). Cells were 381 
stained with conjugated antibodies for 30 min at 4°C in the dark in PBS/0.5% BSA. 7AAD 382 
(1:20; eBioscience/ThermoFisher) or Fixable Viability Dye eFluor 780 (1:1000; 383 
eBioscience/ThermoFisher) was added to exclude dead cells. For intracellular cytokine 384 
staining, single-cell suspensions were stimulated in IMDM containing 8% FCS, 100 IU/mL 385 
penicillin, 100 mg/mL streptomycin, 0.5% β-mercaptoethanol, 50 ng/ml PMA, 1 mM ionomycin 386 
and Golgi-Plug (1:1,000; BD Biosciences) for 3h at 37°C. Surface antigens were stained first, 387 
followed by fixation and permeabilization using the Cytofix/Cytoperm kit (BD Biosciences) and 388 
staining of intracellular proteins. All antibodies used are listed in Extended Data Table 1. All 389 
experiments were performed using a BD LSR II flow cytometer using Diva software or the 390 
Beckman Coulter CyAn ADP flow cytometer using Summit software. Data analyses were 391 
performed using FlowJo Software version 9.9.  392 
 393 
Cell culture 394 
Mouse cell lines were generated as follows: Wap-cre;Cdh1F/F;AktE17K (WEA) and Wap-395 
cre;Cdh1F/F;Pik3caE545K (WEP) tumour material was collected in ice-cold PBS and 396 
mechanically chopped using a McIlwain tissue chopper (Mickle Laboratory Engineering). 397 
Tumours were subsequently digested for 30 min at 37°C in 3 mg/mL Collagenase A, 0.1% 398 
trypsin and fungizone in DMEM/2% FCS. Enzyme reactions were stopped by addition of 399 
DMEM/2% FCS and suspensions were dispersed through a 40 µm cell strainer. Cells were 400 
initially cultured in DMEM containing 10% FCS, 100 IU/mL penicillin, 100 mg/mL streptomycin, 401 
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Insulin, EGF and Cholera toxin. After establishment, mouse cell lines were cultured in DMEM 402 
medium supplemented with 8% FCS, 100 IU/mL penicillin, 100 mg/mL streptomycin and 2 mM 403 
L-glutamine. To ensure relatedness to parental GEMM tumours, polyclonal cells were used at 404 
low passage number for all experiments. MCF-7 cells were cultured in DMEM medium 405 
supplemented with 8% FCS, 100 IU/mL penicillin, 100 mg/mL streptomycin and 2 mM L-406 
glutamine. For in vitro culture of bone marrow-derived macrophages (BMDMs), bone marrow 407 
was aseptically collected by flushing tibia and femurs from euthanized WT mice with sterile 408 
RPMI/8% FCS. Bone marrow cells were cultured for 7 days in RPMI medium supplemented 409 
with 8% FCS, 100 IU/mL penicillin, 100 mg/mL streptomycin and 10 ng/mL recombinant M-410 
CSF (Peprotech). BMDMs were harvested at day 7 and examined for CD11b and F4/80 411 
expression by flow cytometry. Consistent purities of >95% CD11b+F4/80+ cells were obtained. 412 
For in vitro culture of human monocyte-derived macrophages (MDMs), human PBMCs 413 
(Sanquin, Amsterdam) were enriched by magnetically activated cell sorting (MACS) using 414 
CD14 microbeads (Miltenyi Biotec). CD14+ cells were cultured in RPMI medium supplemented 415 
with 8% FCS, 100 IU/mL penicillin, 100 mg/mL streptomycin and 10 ng/mL recombinant M-416 
CSF (Peprotech). MDMs were harvested at day 7 and examined for CD11b, CD14 and CD68 417 
expression by flow cytometry. Consistent purities of >95% CD11b+CD14+CD68+ cells were 418 
obtained. Where indicated, BMDMs and MDMs were exposed to conditioned medium (CM) 419 
from tumour cell lines, in presence or absence of LGK974 (1 µM, Selleck Chemicals) for 24 h 420 
and harvested for RNA and/or protein isolation. CM was obtained by culturing tumour cells at 421 
equal confluency in empty DMEM overnight. Cell growth kinetics in vitro were analysed using 422 
the IncuCyte System (Essen BioScience). 423 
 424 
RNA isolation and quantitative RT-PCR 425 
RNA was isolated using either Trizol or a Qiagen Rneasy column followed by treatment with 426 
Dnase I (Invitrogen). RNA quality was confirmed with a 2100 Bioanalyzer from Agilent. RNA 427 
was converted to complementary DNA (cDNA) with an AMV reverse transcriptase using 428 
Oligo(dT) primers (Invitrogen). cDNA (20 ng per well) was analysed by SYBR green real-time 429 
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PCR with 500 nM primers using a LightCycler 480 thermocycler (Roche).  -actin and/or 430 
GAPDH were used as reference genes. Primer sequences used for each gene are listed in 431 
Extended Data Table 2. Fold change in expression was calculated using 2–(ΔCt.x – average[ΔCt.control]).  432 
 433 
Protein isolation and western blotting 434 
Protein lysates of cells and tissue were prepared using RIPA buffer (50 mM Tris-HCl, pH 7.4, 435 
150 mM NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 2 mM EDTA) complemented with protease 436 
and phosphatase inhibitors (Roche) and protein concentration was quantified using the BCA 437 
protein assay kit (Pierce). Protein lysate was loaded onto NuPAGE 4–12% Bis-Tris gradient 438 
gels (Invitrogen) and transferred onto Trans-Blot® Turbo™ Mini or Midi Nitrocellulose 439 
membranes (BioRad) using Trans-Blot Turbo Transfer System (BioRad). Membranes were 440 
blocked in 10% Western Blot Blocking Reagent (Roche) or 3% BSA for 1 h at room 441 
temperature (RT). Primary antibody incubation was performed overnight at 4°C. Membranes 442 
were washed using TBS-T and subjected to secondary fluorochrome-conjugated antibodies 443 
for 1 h at RT and protein was detected using the Odyssey CLx imaging system and processed 444 
using ImageJ software 1.48v. Antibodies are listed in Extended Data Table 1.  445 
 446 
Immunohistochemistry  447 
Immunohistochemical analyses were performed by the Animal Pathology facility at the 448 
Netherlands Cancer Institute. Formalin-fixed tissues were processed, sectioned and stained 449 
as described36. Briefly, tissues were fixed for 24 h in 10% neutral buffered formalin, embedded 450 
in paraffin, sectioned at 4 μm and stained with haematoxylin and eosin (H&E) for 451 
histopathological evaluation. H&E slides were digitally processed using the Aperio ScanScope 452 
(Aperio, Vista, CA). For immunohistochemical analysis, 5 μm paraffin sections were cut, 453 
deparaffinised and stained. Antibodies and antigen retrieval methods are listed in Extended 454 
Data Table 1. Quantitative analysis of cell abundance was performed by counting cells in five 455 
high-power (x40) fields of view (FOV) per tissue by two independent researchers. Samples 456 
were visualized with a BX43 upright microscope (Olympus) and images were acquired in bright 457 
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field using cellSens Entry software (Olympus). To score pulmonary metastasis, single lung 458 
sections were stained for cytokeratin-8 and metastatic nodules were counted by two 459 
independent researchers. Stained tissue slides were digitally processed using the Aperio 460 
ScanScope. Brightness and contrast for representative images were adjusted equally among 461 
groups. 462 
 463 
Cytokine analyses  464 
Quantification of cytokine and chemokine levels in serum was performed using BD Cytometric 465 
Bead Array for CCL2, IL-1β, IL-17A and G-CSF according to manufacturer’s instructions and 466 
analysed on a Beckman Coulter CyAn ADP flow cytometer with Summit software. Data 467 
analyses were performed using FlowJo Software version 9.9.  468 
 469 
CRISPR/Cas9-mediated gene disruption 470 
For knock-out of murine Trp53, p53-proficient tumour cell lines were transfected with 471 
lentiCRISPR v2 (provided by Feng Zhang (Addgene plasmid #52961)37) containing sgRNA 472 
targeting exon 4 (sgRNA1: 5’- TCCGAGTGTCAGGAGCTCCT-3’ and sgRNA2: 5’-473 
AGTGAAGCCCTCCGAGTGTC-3’). For knock-out of human TP53, MCF-7 tumour cell lines 474 
were transfected with lentiCRISPRv2 containing sgRNA targeting either exon 4 (sgRNA1: 5’- 475 
CCATTGTTCAATATCGTCCG-3’) or exon 2 (sgRNA2: 5’-TCGACGCTAGGATCTGACTG-3’). 476 
Cloning of sgRNAs in lentiCRISPR was performed as described37 and sgRNA sequences were 477 
designed using the online CRISPR Design tool (http://crispr.mit.edu), of which the two highest 478 
scoring sequences were chosen. All vectors were validated by Sanger sequencing. After 479 
selection of transfected cells, polyclonal cell lines were used for all subsequent experiments. 480 
To determine knock-out efficiency, genomic DNA from cell lines was isolated using Viagen 481 
DirectPCR Lysis reagent (Cell) supplemented with 200 µg/mL proteinase K after transfection 482 
and puromycin selection. Murine Trp53 target region was amplified using PCR with the 483 
following primers: FW 5’-GGGGACTGCAGGGTCTCAGA-3’ and RV 5’-484 
CCACGTCCCCTGGAGAGATG-3’. Human TP53 target region was amplified using PCR with 485 
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the following primers: FW1 5’-CAGACTGCCTTCCGGGTCAC-3’ for sgRNA1, FW2 5’-486 
TGGGAAGGTTGGAAGTCCCTC-3’ for sgRNA2, and RV 5’-487 
CACTGACAGGAAGCCAAAGGG-3’. PCR products were run on 1% agarose gel, purified 488 
using the Illustra GFX™ PCR DNA and Gel Band Purification Kit (Sigma), and subjected to 489 
Sanger sequencing using their respective FW primers. Genome editing efficiency was 490 
quantified using the Tracking of Indels by Decomposition (TIDE) algorithm as described 491 
(http://tide.nki.nl)38.  492 
 493 
shRNA- and siRNA-mediated knock-down of genes 494 
Vectors for shRNAs were collected from the TRC library. To allow stable expression of 495 
shRNAs, HEK293T cells were transfected with the pLKO.1 lentiviral vector encoding shRNAs, 496 
pPAX packaging vector and VSV-G envelope vector. Five independent shRNA clones were 497 
used for each experiment. Virus was harvested at day 4 and 5 and viral titres were determined 498 
using the Abm qPCR lentivirus titration kit (LV900). Cells lines were subsequently transduced 499 
and selected using puromycin. Knock-down efficiency was determined by RT-qPCR as 500 
compared to non-targeting controls. The shRNA clone used for Porcupine knock-down in all 501 
experiments after assessment of knock-down efficiency contained following hairpin sequence: 502 
5’-CAACTTTCTATGCCTGTCAAT-3’ (shPorcn-1) or 5’-CCCATGTCTTATTGGTTAAAT-3’ 503 
(shPorcn-4). For in vivo experiments, shPorcn-4 was used. To silence Fzd receptors, BMDMs 504 
were transfected with the following siRNA pools (control siRNA (sc-37007), Fzd7 (sc-39991), 505 
and Fzd9 (sc-39995), Santa Cruz Biotechnology), according to manufacturer’s instructions. 506 
Briefly, BMDMs were differentiated as described above, and 24 h before exposure to tumour 507 
CM and BMDMs were suspended in transfection medium and incubated with indicated siRNA 508 
pools. After 6 h at 37°C, 2X RPMI medium was added (RPMI, 20% serum, 200 IU/mL penicillin, 509 
200 mg/mL streptomycin and 20 ng/mL recombinant M-CSF) and BMDMs were further 510 
cultured overnight. After 24 h, the medium was replaced by tumour CM for 24 h, after which 511 
gene expression was assessed.     512 
 513 
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Chromatin immunoprecipitation (ChIP)-sequencing 514 
ChiP-seq was performed as previously described39. Briefly, cell lines from Wap-515 
cre;Cdh1F/F;AktE17K and Wap-cre;Cdh1F/F;Pik3caE545K tumours (3 cell lines from 3 independent 516 
mouse tumours per genotype) were fixed in 1% formaldehyde, crosslinked and processed for 517 
sonication. 5 µg of p53 antibody (Extended Data Table 1) and 50 µL of Protein G magnetic 518 
beads (Invitrogen) were used for each ChIP. Eluted DNA was sequenced using the Illumina 519 
Hiseq 2500 analyser (using 65 bp reads) and aligned to the Mus musculus mm10 reference 520 
genome. Peak calling over input control was performed using and MACS 2.0 peak caller. Data 521 
was visualized using Easeq40. 522 
 523 
Overexpression of miR-34a 524 
The MSCV-miR-34a retroviral vector (provided by Lin He (Addgene plasmid #63932)41) was 525 
transfected in HEK293T cells, together with pGag-Pol and VSV-G vectors to generate 526 
retrovirus. Mouse cancer cell lines were exposed to viral supernatant and assessed for 527 
expression of Wnt target genes after puromycin selection.   528 
 529 
RNA sequencing and analysis 530 
Total RNA was extracted from tumours using TRIzol reagent (Ambion Life Technologies) 531 
according to the manufacturer’s instructions. Samples were equimolar pooled and were single-532 
end sequenced for 51 or 65 base pairs on the Illumina Hiseq2000/Hiseq2500 Machine. The 533 
reads were aligned against the mouse transcriptome (mm10) using Tophat2 (Tophat version 534 
2.1.0 / Bowtie version 1.0.0) that allows for exon-exon junctions42,43. Tophat was guided using 535 
a reference genome as well as a reference transcriptome. The reference transcriptome was 536 
created using a gene transfer file (GTF) that was downloaded from Ensembl (version 77). 537 
Gene counts were generated using a custom script, that functions identically to HTSeq-count44. 538 
Only reads that mapped uniquely to the transcriptome were used for gene expression 539 
quantification. While some of the libraries were generated with strand-specific protocols, all 540 
samples have been aligned without taking strandedness into account. Next, differential 541 
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expression analysis was performed using the R package edgeR45 in combination with the 542 
voom46 method, using raw read counts as input. Library size normalisation was performed 543 
during differential expression analysis within the voom function. Genes with P-values < 0.05 544 
were labelled as differentially expressed. Genes were further filtered for display by requiring 545 
them to be protein coding and to have an absolute log2 fold change ≥ 3 and a P-value ≤ 0.01. 546 
The selected genes were shown in a heatmap of readcounts that were normalized to 10 million 547 
reads per sample.  548 
For Hallmark pathway analysis of murine transcriptomes, raw read counts were 549 
normalised by trimmed means of M-values computed using the function calcNormFactors 550 
(edgeR version 3.20.545), from which CPM-normalized gene expression values were computed 551 
for plotting purposes using the same R-package. CPM-values were subsequently transformed 552 
as f(x) = log2(x + 1). Ensembl77 murine gene identifiers were then converted to homologous 553 
human gene identifiers using the biomaRt-R package (server oct2016.archive.ensembl.org). 554 
Gene expression heatmaps for hallmark human gene sets obtained from MsigDB47 were 555 
generated using the aheatmap-function provided by the NMF R-package (version 0.20.6). 556 
Heatmap columns (containing samples) were ordered according to average linkage (UPGMA) 557 
hierarchical sample-clustering based on Pearson correlation-distances between the 558 
expression values of displayed genes. Heatmap rows (containing genes) were ordered 559 
according to gene expression fold difference between Trp53—/— and Trp53+/+ samples. The R 560 
language for statistical computing was used (version 3.4.2) for gene expression normalisation 561 
and heatmap generation. Pathway enrichment analysis of Trp53—/— and Trp53+/+ tumours was 562 
performed using Ingenuity Pathway Analysis software (QIAGEN), analysing differentially 563 
expressed genes with P ≤ 0.05. 564 
 565 
The Cancer Genome Atlas (TCGA) analysis 566 
To obtain a comprehensive view on the cellular processes affected by p53-deficiency in human 567 
breast cancer, we performed a gene set enrichment analyses (GSEA) using a 50 hallmark 568 
gene sets (Liberzon)47 on the TCGA breast cancer (BRCA) cohort. First, we classified p53-569 
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deficiency based on mutational status. DNA sequencing variant calls (MAF-file) for the BRCA 570 
cohort were downloaded from the 2015-08-21 release of the Broad TCGA genome data 571 
analysis centre standard run (http://gdac.broadinstitute.org/runs/stddata). We utilized two 572 
classifications for p53-deficiency: in the first classification (labelled ‘any TP53 mutation’), 573 
patients with any kind of TP53 mutation were classified as p53-deficient. In the second 574 
classification (labelled ‘IARC TP53 database’), only patients with a dominant negative TP53 575 
mutation as annotated using the IARC TP53 mutation database48 (release 18, matched on 576 
protein effect of the mutation) were labelled as p53-deficient, as well as patients with gain-of-577 
stop, stop-lost or frameshifting mutations (n=161). One sample had a trans-activating mutation 578 
and was excluded from the analysis. The remaining samples were labelled as p53-proficient 579 
(n=793). 580 
Next, TCGA RNA sequencing data were downloaded from the Broad TCGA genome 581 
data analysis centre 2015-11-01 release of the standard runs. We ran a gene set enrichment 582 
analysis (GSEA) on the 50 Hallmark gene set using the flexgsea-r R package 583 
(https://github.com/NKI-CCB/flexgsea-r) on the read counts normalized with limma voom with 584 
the span parameter set to 0.546. Within each permutation of the sample labels, genes were 585 
ranked for association with p53-proficiency using the moderated t-statistic from the limma 586 
empirical Bayes function (ebayes() ran on the result of lmFit()). Reported FDR-values were 587 
obtained from the flexgsea-r output. 588 
Single gene associations with TP53 status in human breast tumours of the TCGA 589 
BRCA cohort and correlation coefficients between WNT-related genes and TP53 status (MUT 590 
vs WT) were analysed using R2 Genomics Analysis and Visualization Platform 591 
(http://r2.amc.nl/) and visualized using GraphPad Prism version 7.  592 
 593 
Statistics and reproducibility 594 
Data analyses were performed using GraphPad Prism (version 7). The statistical tests used 595 
are described in figure legends. All tests were performed two-tailed. P-values < 0.05 were 596 
considered statistically significant. All western blot and RT-qPCR analyses were independently 597 
 25 
repeated more than twice. Sample sizes were based on previous experiments5,17,36 or 598 
determined using G*Power software (version 3.1). To exclude bias towards one particular 599 
GEMM in the analyses for Figure 1, we have performed the same analyses on the average of 600 
the neutrophil levels and serum cytokine values per model. This demonstrated the same 601 
correlations between the assessed values and p53 status of the tumour, thus excluding bias 602 
towards one or several particular models. Principal component analysis was performed using 603 
the prcomp-function in R (version 3.4.2), both centering and scaling the input data before 604 
applying dimensionality reduction. 605 
 606 
Reporting summary 607 
Further information on research design is available in the Nature Research Reporting 608 
Summary linked to this paper.  609 
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Extended Data Figure legends 657 
 658 
Extended Data Figure 1. Neutrophil expansion in p53-deficient tumour-bearing GEMMs. 659 
a. Representative plots of flow cytometry analysis on blood of end-stage (cumulative tumour 660 
size 1500 mm3) mammary tumour-bearing mice. Neutrophils were defined as 661 
CD11b+Ly6G+Ly6C+. cKIT expression on gated total neutrophils in blood is shown (gating was 662 
based on blood of WT mice). Quantification and statistical analysis of these data is found in 663 
Fig. 1a, b. 664 
 665 
Extended Data Figure 2. CRISPR/Cas9-mediated gene disruption of Trp53 in Wap-666 
cre;Cdh1F/F;AktE17K and Wap-cre;Cdh1F/F;Pik3caE545K cancer cell lines. a. Insertion and 667 
deletion (indel) spectrum of bulk Wap-cre;Cdh1F/F;AktE17K (WEA) cancer cell lines after 668 
transfection with 2 individual sgRNAs against Trp53 and puromycin selection, as determined 669 
by the TIDE algorithm and compared to the sequence of target region of control cells. The P-670 
value associated with the estimated abundance of each indel is calculated by a two-tailed t-671 
test of the variance–covariance matrix of the standard errors. b. Western blot analysis showing 672 
p53 levels of control and p53-knockout (KO) WEA cell lines. Inactivation of the p53 pathway is 673 
shown by loss of p21 staining after 10 Gy irradiation. KO1 (sgRNA1) resulted in a truncated 674 
p53 protein and KO2 (sgRNA2) shows absence of p53 protein. For all subsequent 675 
experiments, KO2 was used. Representative of two independent experiments. For uncropped 676 
images, see Supplemental Fig. 1. c. In vitro growth kinetics of WEA control and p53-KO cells, 677 
as determined by IncuCyte (n=7 technical replicates/group). d. In vivo growth kinetics of 678 
orthotopically transplanted WEA;Trp53+/+ (n=4 mice) and WEA;Trp53–/– (n=6) cancer cell lines, 679 
with t = 0 being the first day tumours were palpable. e. Indel spectrum of bulk Wap-680 
cre;Cdh1F/F;Pik3caE545K (WEP) cancer cell lines after transfection with sgRNA2 against Trp53 681 
and puromycin selection, as determined by the TIDE algorithm. f. In vitro growth kinetics of 682 
WEP control and p53-KO cells, as determined by IncuCyte (n=7 technical replicates/group). g. 683 
In vivo growth kinetics of orthotopically transplanted WEP;Trp53+/+ (n=5) and WEP;Trp53–/– 684 
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(n=5) cell lines, with t=0 being the first day tumours were palpable. h. Gating strategy to identify 685 
circulating neutrophils and their cKIT expression. i. Gating strategy to identify neutrophils in 686 
the lung. j. Representative images of spleens from mice bearing WEA;Trp53+/+ and 687 
WEA;Trp53–/– tumours and quantification of spleen area (length x width) at end-stage (tumour 688 
volume 1500 mm3) of mice bearing p53-proficient  (n=4) and p53-deficient WEA (n=6) and 689 
WEP tumours (n=5/group). All data are means ± s.e.m. P-values are indicated as determined 690 
by Area Under the Curve followed by two-tailed Welch’s t-test (c, d, f , g) or two-tailed Mann-691 
Whitney U-test (j), ns: not significant.  692 
 693 
Extended Data Figure 3. Haematopoiesis in p53-null tumour-bearing mice is skewed 694 
towards the development of neutrophils. a. Schematic representation of neutrophil 695 
development in the bone marrow. b. Gating strategy of neutrophil progenitor populations in the 696 
bone marrow. Dot plot indicates the cKIT expression levels (median fluorescence intensity 697 
[MFI]) in promyelocytes compared to mature neutrophils (n=20 mice). c. Frequency of bone 698 
marrow progenitor populations in mice bearing end-stage Wap-cre;Cdh1F/F;AktE17K;Trp53+/+ 699 
(n=9) and Wap-cre;Cdh1F/F;AktE17K;Trp53–/– (n=11) tumours, as determined by flow cytometry. 700 
d. Total live cells and total live progenitor population numbers per hindleg of mice bearing 701 
WEA;Trp53+/+ and WEA;Trp53–/– tumours (n=5/group). All data are ± s.e.m. P-values are 702 
indicated as determined by two-tailed Mann-Whitney U-test. Abbreviations: LSK (Lin–703 
Sca1+cKIT+, which contain the LT-HSC (long-term haematopoietic stem cells), ST-HSC (short-704 
term haematopoietic stem cells) and MPP (multipotent progenitors)), CMP (common myeloid 705 
progenitors), GMP (granulocytic and monocytic progenitors), MEP (megakaryocyte and 706 
erythrocyte progenitors).        707 
 708 
Extended Data Figure 4. Macrophages are differentially activated by Trp53–/– mouse and 709 
human breast cancer cell lines. a. Expression (median fluorescence intensity [MFI]) of 710 
CCR2, CCR6, CD206, CSF-1R, CXCR4 and MHC-II on live CD11b+F4/80+ bone marrow-711 
derived macrophages after exposure to control medium or conditioned medium (CM) of Wap-712 
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cre;Cdh1F/F;AktE17K;Trp53+/+ or Wap-cre;Cdh1F/F;AktE17K;Trp53–/– cell lines, as determined by 713 
flow cytometry (n=4 biological replicates/group). b. TIDE analysis of bulk MCF-7 cells after 714 
transfection with TP53-targeting sgRNAs and puromycin selection. For subsequent 715 
experiments, sgRNA1 was used. c. Expression (MFI) of CD206, CD163 and HLA-DR on 716 
human CD11b+CD14+CD68+ monocyte-derived macrophages (MDMs) after exposure to CM 717 
of MCF-7;TP53+/+ or MCF-7;TP53–/– (sgRNA1) cancer cells (n=3 biological replicates/group). 718 
d. RT-qPCR analysis showing IL1B expression in human CD11b+CD14+CD68+ MDMs after 719 
exposure to control medium (n=4 biological replicates) CM of MCF-7-TP53+/+ or MCF-7-TP53–720 
/–cancer cells (n=5 biological replicates/group). Data are normalized to normal medium control. 721 
Plots shows representative data of 3 separate experiments and average with 2 technical 722 
replicates. All data are means ± s.e.m. P-values are indicated as determined by two-tailed one-723 
way ANOVA, Tukey’s multiple-testing correction.  724 
 725 
Extended Data Figure 5. Transcriptome profile and composition of the local tumour 726 
immune landscape in breast cancer GEMMs. a. Unsupervised clustering of top 200 most 727 
differentially expressed genes (P < 0.01, LFC > 3 or < –3) in mammary GEMM tumours as 728 
determined by RNA sequencing (n=145 tumours). Red bars indicate Trp53+/+ tumours, blue 729 
bars indicate Trp53–/– tumours. Full tumour genotype is displayed in legend and shown by 730 
indicated colours. b. Number of Ly6G+ neutrophils in the tumour (n=1, 4, 10, 2, 4, 3, 6, 13, 4, 731 
22, 4 and 5 mice, top to bottom). c. Macrophage score as indicative of F4/80+ macrophage 732 
abundance in the tumour (n=2, 2, 4, 4, 4, 2, 3, 5, 4, 9, 5 and 4 mice, top to bottom). d. Number 733 
of CD8+ cytotoxic T cells in the tumour (n=3, 2, 5, 5, 7, 3, 7, 3, 5, 4, 4 and 5 mice, top to bottom). 734 
e. Number of CD4+ T cells in the tumour (n=3, 2, 5, 5, 7, 3, 7, 3, 5, 4, 4 and 5 mice, top to 735 
bottom). f. Number of Foxp3+ regulatory T cells in the tumour (n=3, 2, 5, 5, 7, 3, 7, 3, 5, 4, 4 736 
and 5 mice, top to bottom). g. Ratio of CD8/Foxp3 cells in the tumour (n=3, 2, 5, 5, 7, 3, 7, 2, 737 
5, 4, 4 and 5 mice, top to bottom). All data are means of 5 microscopic fields of view (FOV) 738 
per mouse as determined by IHC. Inserts show data combined according to p53 status of the 739 
tumour. Each symbol represents an individual mouse. All data are means ± s.e.m. P-values 740 
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are indicated as determined by two-tailed one-way ANOVA, FDR multiple-testing correction 741 
(a) or two-tailed Mann-Whitney U-test (b – g).  742 
 743 
Extended Data Figure 6. Wnt-related gene activation correlates with loss of p53 in 744 
mouse and human breast tumours. a. Heatmap showing that Trp53–/– (KO) GEMM tumours 745 
(n=77) cluster away from Trp53+/+ (WT) tumours (n=68) based on analysis of the Hallmark p53 746 
pathway (represents positive control) and b. analysis of the Hallmark Wnt/-catenin pathway. 747 
Analysis was performed on all tumours of Extended Data Fig. 5a. c. Log2 fold change 748 
expression of genes involved in Wnt signalling (P < 0.05) in Trp53–/– (n=77) and Trp53+/+ (n=68) 749 
GEMM tumours depicted in Extended Data Fig. 5a. Black bars indicate genes that positively 750 
regulate, or are generally increased with active Wnt signalling. Red bars indicate genes that 751 
negatively regulate, or are down-regulated with active Wnt signalling. d. Gene set enrichment 752 
analysis (GSEA) for Hallmark pathways in TCGA TP53WT breast tumours (n=643) vs TP53MUT 753 
(n=351) human tumours (any TP53 mutation) or TP53 loss (based on the IARC TP53 754 
database, see Materials and Methods). Normalized enrichment score is shown with False 755 
Discovery Rate (FDR) indicated. e. Correlation coefficient (R) of all genes involved in Wnt 756 
signalling that correlate significantly (P < 0.05) with TP53MUT (n=351) vs TP53WT (n=643) in 757 
TCGA breast tumours. Black bars indicate genes that positively regulate, or are generally 758 
increased with active Wnt signalling. Red bars indicate genes that negatively regulate, or are 759 
down-regulated with active Wnt signalling. P-values were determined by two-tailed ANOVA 760 
with FDR multiple-testing correction (c, e). 761 
 762 
Extended Data Figure 7. p53 does not bind the regulatory regions of Wnt ligands 763 
directly. a. Chromatin immunoprecipitation-sequencing (ChIP-seq) profile of p53 binding to 764 
DNA demonstrating enrichment on the Cdkn1a (p21) locus in Trp53+/+ Wap-cre;Cdh1F/F;AktE17K 765 
(WEA) and Wap-cre;Cdh1F/F;Pik3caE545K (WEP) cell lines (3 cell lines from 3 independent 766 
tumours per GEMM). b. Absence of p53 binding to Wnt1, Wnt6 or Wnt7a loci. c. Enrichment 767 
of p53 on microRNA-34a (miR-34a) locus. d. RT-qPCR analysis of Wnt ligand expression in 768 
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WEA;Trp53+/+ and WEA;Trp53–/– cell lines after overexpression (OE) of miR-34a in 769 
WEA;Trp53–/–cells (n=3 technical replicates/group). Plots show representative data of 3 770 
separate experiments with 3 technical replicates. All data are means ± s.e.m. P-values are 771 
indicated as determined by two-tailed one-way ANOVA, Tukey multiple-testing correction (d). 772 
 773 
Extended Data Figure 8. Macrophages are activated by Trp53–/– cancer cells via Fzd7 774 
and Fzd9 receptors in vitro. a. Log2 fold change in expression of Wnt receptors Fzd7 and 775 
Fzd9 in bulk tumours comparing Trp53–/– (n=77) and Trp53+/+ (n=68) GEMM tumours using 776 
RNA-sequencing. b. Expression of FZD7 and FZD9 in TP53 wild-type (WT, n=643) and TP53 777 
mutant (MUT, n=351) human breast tumours of TCGA dataset. c. Silencing of Fzd7 and Fzd9 778 
in bone marrow-derived macrophages (BMDMs) after transfection with siRNA pools against 779 
both receptors, as determined by RT-qPCR (n=6 biological replicates/group). d. Expression of 780 
Il1b in BMDMs after exposure to conditioned medium of Trp53+/+ and Trp53–/– Wap-781 
cre;Cdh1F/F;AktE17K cell lines (n=6 biological replicates/group), as determined by RT-qPCR. 782 
Where indicated, BMDMs were transfected with control siRNA or Fzd7/9 siRNA pools. a, c, d 783 
show means ± s.e.m. b. shows 5 – 95 percentile boxplot with median and quartiles indicated. 784 
P-values are indicated as determined by two-tailed one-way ANOVA, FDR multiple-testing 785 
correction (a), two-tailed Mann-Whitney U-test (b) or two-tailed one-way ANOVA, Tukey 786 
multiple-testing correction (d). 787 
 788 
Extended Data Figure 9. Pharmacological and genetic targeting of Porcupine in p53-789 
deficient tumours reduces systemic inflammation. a. Total and cKIT+ neutrophil 790 
frequencies in lungs of vehicle (n=7) or LGK974 (n=4)-treated K14cre;Cdh1F/F;Trp53F/F (KEP) 791 
mice using indicated 5 day short-term treatment schedule. Representative flow cytometry plots 792 
are shown. b. Frequency of IL-17A-producing  T cells in lungs of vehicle (n=6) or LGK974 793 
(n=4)-treated KEP mice. Representative flow cytometry plots are shown. c. Kinetics of 794 
circulating neutrophils in vehicle or LGK974-treated KEP mice using indicated long-term 795 
treatment schedule, shown as frequency at indicated tumour volumes (n=8/group). d. RT-796 
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qPCR analysis of Porcn expression in end-stage bulk tumour (n=5/group). Data are normalized 797 
to shControl and represents an average of 2 technical replicates. e. Correlation of total 798 
neutrophil levels in circulation with expression of Porcn in WEA;Trp53–/–;shControl and 799 
WEA;Trp53–/–;shPorcn whole tumour lysate (n=5/group). f. Correlation of cKIT+ neutrophil 800 
levels in circulation with expression of Porcn in WEA;Trp53–/–;shControl and WEA;Trp53–/–801 
;shPorcn whole tumour lysate (n=5/group). g. Correlation of Porcn expression and Il1b 802 
expression in bulk WEA;Trp53–/–;shControl (blue) and WEA;Trp53–/–;shPorcn tumours (grey) 803 
(n=5/group). Data represent an average of 2 technical replicates. h. Spleen area in mice with 804 
WEA;Trp53–/–;shControl (blue) and WEA;Trp53–/–;shPorcn tumours (grey) tumours at end-805 
stage (n=5/group). i.  Growth kinetics of orthotopically transplanted KEP mammary tumours, 806 
treated with vehicle (n=12) or LGK974 (n=15). Each line represents an individual mouse. j.  807 
Growth kinetics of orthotopically injected Trp53+/+ and Trp53–/– Wap-cre;Cdh1F/F;Pik3caE545K 808 
(WEP) cells, treated with vehicle or LGK974. Each line represents an individual mouse 809 
(n=9/group). k. Schematic representation of the findings of this study: loss of p53 in breast 810 
cancer cells triggers secretion of Wnt ligands to activate tumour-associated macrophages. This 811 
stimulates systemic expansion and activation of neutrophils, which we have previously shown 812 
to be immunosuppressive5, thus driving metastasis. All data are means ± s.e.m. P-values are 813 
indicated as determined by two-tailed Mann-Whitney U-test (a – d, h) and R2 and P-values 814 
determined by linear regression analysis (e – g).  815 
816 
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